Public deck
CRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary risk
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
Public deck
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.